BioCentury
ARTICLE | Strategy

Meeting the Biota Quota

December 7, 2009 8:00 AM UTC

Biota Holdings Ltd.'s acquisition of MaxThera Inc. and Prolysis Ltd. fills some holes in its pipeline, which should help it achieve its long-term goal of having two or three out-licensed, royalty-generating compounds on the market at all times.

Biota receives royalties from GlaxoSmithKline plc for sales of Relenza zanamivir, an inhaled neuraminidase inhibitor marketed to prevent and treat influenza infection. In its FY09 ended June 30, Biota received A$45 million ($36.5 million) in Relenza royalties, up from A$20.5 million ($19.6 million) in FY08...